• Shares of Tetraphase Pharmaceuticals $TTPH have dropped more than 90% off their high and the lead antibiotic failed a Phase III, but CEO Guy Macdonald is still touting eravacycline’s commercial potential. The antibiotic could earn $700 million a year, he told Reuters. “We just need the data,” Macdonald said. And how.
• Portola $PTLA says that the FDA doesn’t plan to hold an AdComm meeting for betrixaban, their Factor Xa inhibitor anticoagulant. “Based on the APEX data, we remain confident in the potential for betrixaban to be approved as the first anticoagulant for extended-duration VTE prophylaxis in high-risk acute medically ill patients,” said John T. Curnutte, MD, PhD, executive vice president, research and development, at Portola. Portola was slammed last year when the FDA rejected its anti-anticoagulant andexanet alfa.
• The competition to host the relocated HQ for the EMA in a post-Brexit world is heating up. Denmark has now thrown its hat in the ring, suggesting that Copenhagen would be an ideal location. Denmark has a special envoy to help make its case. Ex-Novo Nordisk CEO Lars Rebien Sørensen is out front, talking up Copenhagen’s merits.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription